Ajanta Pharma Limited (APL) is a pharmaceutical company headquartered in Mumbai, India. It has strong presence in Branded Generic business in India & Emerging markets; and Generic business in USA. In India, company operates in selected therapeutic areas of Cardiology, Dermatology, Ophthalmology and Pain management. Its brands in each of sub-therapeutic areas or molecules hold leadership positions. In Emerging Markets, company has presences in Africa, Asia, Middle East, and CIS on broader therapeutic segments such as anti-malarial, gastro, antibiotics, cardiology, dermatology, pain management, etc. In USA, company has already no. of approved ANDAÍs which are either commercialized or in process of being commercialized and large no. of ANDAÍs are awaiting US FDA approval. We have state-of-the-art research facilities for formulation and API development located at Mumbai, India. Our R&D capabilities are evident from number of products launched 1st to market by the company providing patients most needed compliance and convenience. A dedicated and focused team of more than 800 Ajantaites work for R&D, which is growing continuously. Ajanta has Six formulations manufacturing facilities located in India and 1 in Mauritius. Besides that, we also have an API manufacturing facility located at Waluj, India. AjantaÍs flagship formulation facility at Paithan (Maharashtra, India) and Dahej (Gujarat, India) is successfully inspected by USFDA. We continuously invest in enhancing our existing manufacturing facilities to meet current cGMP requirements and also construct new facilities to meet the companyÍs growth requirements. We continuously invest in enhancing our existing manufacturing facilities to meet current cGMP requirements and also construct new facilities to meet companyÍs growth requirements. Please visit http://ajantapharma.com/ for more information.